{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:27Z","timestamp":1791176847616,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,9,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To evaluate efficacy and safety of iodine-131 (<jats:sup>131<\/jats:sup>I) \u2013rituximab chimeric anti-CD20 antibody radioimmunotherapy in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> After a standard loading dose of rituximab 375 mg\/m<jats:sup>2<\/jats:sup>, individualized dosimetry was performed by whole-body gamma imaging of a tracer activity of <jats:sup>131<\/jats:sup>I-rituximab followed by administration of a therapeutic activity of <jats:sup>131<\/jats:sup>I-rituximab to deliver an estimated whole-body radiation absorbed dose of 0.75 Gy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Ninety-one patients were entered onto the trial: 78 patients (86%) had follicular lymphoma, six patients (7%) had mucosa-associated lymphoid tissue\/marginal zone lymphoma, and seven patients (8%) had small lymphocytic lymphoma. The objective overall response rate (ORR) was 76%, with 53% attaining a complete response (CR) or CR unconfirmed (CRu). Median duration of response for patients achieving CR\/CRu was 20 v 7 months for those with a partial response (P = .0121). Median progression-free survival for the entire cohort was 13 months, with 14% remaining relapse free beyond 4 years. Median follow-up was 23 months, with a 4-year actuarial survival rate of 59% \u00b1 10%. Toxicity was principally hematologic; grade 4 thrombocytopenia occurred in 4% and neutropenia occurred in 16% of patients, with nadirs at 6 to 7 weeks after treatment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> <jats:sup>131<\/jats:sup>I-rituximab radioimmunotherapy of relapsed or refractory indolent NHL achieves high ORR and CR rates with minimal toxicity. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.05.3470","type":"journal-article","created":{"date-parts":[[2006,8,29]],"date-time":"2006-08-29T02:11:39Z","timestamp":1156817499000},"page":"4418-4425","source":"Crossref","is-referenced-by-count":80,"title":["Multicenter Phase II Clinical Study of Iodine-131\u2013Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1200","volume":"24","author":[{"given":"Michael F.","family":"Leahy","sequence":"first","affiliation":[{"name":"From the University of Western Australia, Fremantle Hospital, Fremantle, Western Australia; and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"From the University of Western Australia, Fremantle Hospital, Fremantle, Western Australia; and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[{"name":"From the University of Western Australia, Fremantle Hospital, Fremantle, Western Australia; and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Harvey","family":"Turner","sequence":"additional","affiliation":[{"name":"From the University of Western Australia, Fremantle Hospital, Fremantle, Western Australia; and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1269\/jrr.46.241"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.0892"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1089\/108497803322287583"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1259"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4690"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-200512000-00001"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.055"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10305"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1692-9"},{"key":"R21","unstructured":"Gregory SA, Leonard J, Coleman A et al: Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I-131 tositumomab. Proc Am Soc Clin Oncol 22:575, 2003 (abstr 2314)"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1007\/BF03027399"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1089\/108497803322287565"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1798-8"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.052"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.040"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.01.017"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2005.02.006"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1770-7"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.05.3470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:22:41Z","timestamp":1653513761000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.05.3470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,20]]},"references-count":30,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2006,9,20]]}},"alternative-id":["10.1200\/JCO.2005.05.3470"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.05.3470","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,20]]}}}